# Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

> **NCT04789668** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Hematopoietic and Lymphoid Cell Neoplasm
- Hormone Receptor Positive Breast Adenocarcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Triple-Negative Breast Carcinoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Bintrafusp Alfa
- **DRUG:** Pimasertib
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04789668
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-15
- **Primary completion:** 2023-12-08
- **Final completion:** 2023-12-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Insufficient accrual
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789668, "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04789668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*